NCT00437723View on ClinicalTrials.gov

A Study of NeoRecormon in Patients With Chronic Kidney Disease.

PHASE4CompletedINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

Not specified

Study Completion Date

April 30, 2008

Conditions

Anemia

Interventions

DRUG

epoetin beta [NeoRecormon]

At a dose to achieve and maintain an Hb level of 120-135g/dL.

Trial Locations (2)

11000

Belgrade

21000

Novi Sad

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY